Tuesday, March 9, 2021

AstraZeneca, Oxford say Covid vaccine shows 70% efficacy

The 70% average is lower compared with the efficacy of coronavirus vaccines trialled by rivals Pfizer/BioNTech and Moderna which have come in above 90%.

Other News

Fashion giant H&M delays ordering new clothing from Myanmar suppliers

The company has around 45 direct suppliers in Myanmar, and has sourced clothing in the country for seven years.

Italy’s virus death toll tops 100,000

Italy will start using the AstraZeneca/Oxford vaccine on people over the age of 65, while it also has high hopes for the single-dose Johnson & Johnson vaccine, which could win EU approval on March 11.

Ahli Parlimen Upko nafi lompat parti sokong PN

Berita palsu itu sengaja dibuat oleh pihak tertentu untuk mewujudkan ketidakstabilan dalam pembangkang.

IBR beri impak besar pertingkat kesedaran tangani rasuah

IBR menjadi pembuka pintu kepada agensi untuk melaksanakan program susulan berkaitan antirasuah.

Gabungan Umno-PH pecahkan ummah

Saya tersenarai dalam lingkungan tiga juta ahli Umno, sekadar ahli akar umbi yang masih taat pada parti. Saya masih peduli dengan nasib parti yang saya...

British drugs group AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against Covid-19 has shown “an average efficacy of 70%” in trials.

“This vaccine’s efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency,” AstraZeneca chief executive Pascal Soriot said in a statement.

The results ranged between 62% and 90% efficacy depending on the vaccine dosage.

The 70% average is lower compared with the efficacy of coronavirus vaccines trialled by rivals Pfizer/BioNTech and Moderna which have come in above 90%.

Monday’s statement said “positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing Covid-19… and no hospitalisations or severe cases of the disease were reported in participants”.

It added: “One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart.”

The pair said that regimen n=8,895 showed 62% efficacy when given as two full doses at least one month apart.

“The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%.”

AstraZeneca said it would “immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval”.

It added that it would seek emergency-use listing from the World Health Organization to accelerate vaccine availability in low-income countries.

AstraZeneca said it is looking at a capacity of up to three billion doses of the vaccine in 2021 pending regulatory approval.

It said the vaccine can be stored, transported and handled “at normal refrigerated conditions” of between two and eight degrees Celsius for at least six months.

‘Save many lives’

More than 23,000 adults are currently being assessed in the trials, with the number expected to rise to up to 60,000, the statement said.

“Clinical trials are also being conducted in the US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries,” it added.

Oxford professor Andrew Pollard said the latest findings show “an effective vaccine that will save many lives”.

“Excitingly, we’ve found that one of our dosing regimens may be around 90 percent effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.

“Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard-working and talented team of researchers based around the world,” added Pollard, who is chief investigator of the Oxford Vaccine Trial.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Italy’s virus death toll tops 100,000

Italy will start using the AstraZeneca/Oxford vaccine on people over the age of 65, while it also has high hopes for the single-dose Johnson & Johnson vaccine, which could win EU approval on March 11.

Fully-vaccinated people can gather without masks, says US health agency

The new guidance does not apply to meetings with people who have underlying conditions that place them at higher risk for severe Covid-19.

India’s richest state has half of all new Covid-19 cases

India’s tally of over 11 million infections is the world’s highest after the US, but as a proportion of its population, India’s virus deaths rank among the lowest in the world.

Malaysia considering single-dose CanSino vaccine

Khairy Jamaluddin says the government might opt for the Chinese vaccine over the US' Johnson & Johnson, supplies of which can only arrive at the end of the year.

Beating misinformation in Bangladesh sex worker vaccine drive

Bangladesh is one of the few Muslim nations where prostitution is legal for women aged over 18, and at least 11 brothels operate in the country of 168 million.